Document:

Exhibit 10.1

 

AMENDMENT NO. 3 TO EXECUTIVE COMPENSATION
AGREEMENT

 

This Amendment No.
3, dated as of October 14, 2020, and effective as of September 1, 2020, (“Amendment No. 3”), to the Executive
Compensation Agreement, effective as of January 1, 2015, as amended by Amendment No. 1, effective as of December 30, 2015, as further
amended by Amendment No. 2, effective as of January 1, 2017, (as so amended, the “Executive Compensation Agreement”)
is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Gerald W. Crabtree (“Executive”).
The Company and the Executive are each referred to in this Amendment No. 3 as a “Party” and collectively as
the “Parties.” Capitalized terms used but not defined in this Amendment No. 3 shall have the meanings given
to them in the Executive Compensation Agreement defined below.

 

The Parties, intending to be legally bound,
hereby agree as follows:

 

1. Section 2 of the
Executive Compensation Agreement is hereby amended and restated to read in its entirety as follows:

 

2. POSITION;
DUTIES. The Executive shall be employed as: (i) a member of the Company’s Board of Directors (“Board”); (ii)
Chief Scientific Officer of the Company; and (iii) Chief Scientific Officer of Viridis Biotech, Inc. and shall have the authorities
and responsibilities customarily associated with the status of such positions at NASDAQ listed companies. In his capacity as Chief
Scientific Officer, the Executive shall report directly to the Chief Executive Officer of the Company. Upon termination of the
Executive’s employment for any reason, if and to the extent requested by the Company, the Executive shall promptly resign
from the Board and from all other positions that the Executive then holds with the Company or any affiliate and promptly execute
all documentation for such resignations.

 

The Executive
shall devote substantially all of his business time, effort and energies to the business of the Company; provided, however, that
notwithstanding the foregoing, the Executive may (a) serve as an officer or director of any of the entities for whom he serves
as such on the Commencement Date or any other entity, (b) engage in civic, charitable, public service and community activities
and affairs, (c) accept and fulfill a reasonable number of speaking engagements, and (d) manage his personal investments and affairs,
as long as such activities do not, in the Executive’s reasonable and good faith judgment, interfere, individually or in the
aggregate, with his obligations and the proper performance his duties and responsibilities to the Company under this Agreement
in any material respect.

 

2. Section 3(A) of
the Executive Compensation Agreement is hereby amended and restated to read in its entirety as follows:

 

(A) Base Salary. The Company
will pay the Executive a base salary at an annual rate of $84,000, payable in accordance with the Company’s usual payroll
practices. The Compensation Committee of the Board may increase the base salary annually in its discretion. The annual rate of
the Executive’s base salary as in effect from time to time is referred to herein as “Base Salary.”

 

3. Except as specifically
provided in and modified by this Amendment No. 3, the Executive Compensation Agreement is in all respects hereby ratified and confirmed.
All references to the “Agreement” or the “Executive Compensation Agreement” shall be deemed to refer to
the Executive Compensation Agreement as such document has been modified by this Amendment No. 3, including, without limitation,
references to the “Agreement” in Section 13 of the Executive Compensation Agreement.

 

4. The provisions of
Section 11 and Section 19 of the Executive Compensation Agreement shall apply to this Amendment No. 3 as if set forth in full in
this Amendment No. 3, mutatis mutandis, and are hereby incorporated by reference in this Amendment No. 3.

 

5. This Amendment No.
3 may be executed in two or more counterparts, each of which shall be deemed an original, but all of which taken together shall
constitute one and the same instrument. Signatures delivered by facsimile or electronic mail, including by PDF, shall be effective
as original signatures for all purposes.

 

 

 

 

 

    	 	1	 

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Amendment No. 3 on the day and year first written above.

 

 

	 	PHARMACYTE BIOTECH, INC.
	 	 	 
	 	By: 	[/s/ Kenneth L. Waggoner]
	 	Name: Kenneth L. Waggoner
	 	Title: Chief Executive Officer,
	 	President and General Counsel
	 	 	 
	 	 	 
	 	EXECUTIVE
	 	 	 
	 	By:	[/s/ Gerald W. Crabtree]
	 	Name: Gerald W. Crabtree
	 	Title: Chief Scientific Officer

 

 

 

 

 

 

 

 

 

 

 

    	 	2Exhibit
10.1

 

AMENDMENT
TO PROMISSORY NOTES

 

This
Amendment to Promissory Notes (this “Amendment”) is entered into as of October 12, 2020, by and between Atlas
Sciences, LLC, a Utah limited liability company (“Lender”), and CBAK
Energy Technology, Inc., a Nevada corporation (“Borrower”). Capitalized terms used in this Amendment
without definition shall have the meanings given to them in the Notes (as defined below).

 

A.
Borrower previously issued to Lender a Promissory Note dated July 24, 2019 in the original principal amount of $1,395,000.00 (the
“Note #1”).

 

B.
Borrower previously issued to Lender a Promissory Note dated December 30, 2019 in the original principal amount of $1,670,000.00
(“Note #2”, and together with Note #1, the “Notes”).

 

C.
Starting on January 27, 2020, Borrower entered into multiple exchange agreements with Lender (the “Exchange Agreements”),
pursuant to each Exchange Agreement, it partitioned a new promissory note in various original principal amounts from the outstanding
balance of the Notes and exchanged the partitioned promissory note for the issuance of shares of the Company common stock to the
Lender.

 

D.
Borrower has requested that Lender amend the Notes to make the outstanding balances convertible into Borrower’s common stock.

 

E.
Lender has agreed, subject to the terms, amendments, conditions and understandings expressed in this Amendment, to make the Notes
convertible.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree
as follows:

 

1.
Recitals. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Amendment are true
and accurate and are hereby incorporated into and made a part of this Amendment.

 

2.
Amendments.

 

(a)
The following sentence shall be added to each of the Notes at the end of Section 4.1:

 

“Borrower’s
failure to deliver Conversion Shares (as defined below) to Lender within three (3) Trading Days (as defined below) of its receipt
of a Conversion Notice (as defined below) shall be considered an Event of Default hereunder. Notwithstanding the foregoing, on
up to three (3) separate occasions, Borrower shall have an additional five (5) Trading Days after the original delivery date to
deliver such Conversion Shares before the occurrence of an Event of Default hereunder.”

 

     

     

    

 

(b)
The following provision shall be added to each of the Notes as Section 17 (with respect to Note #1) and Section 18 (with respect
to Note #2):

 

“17.
Conversion.

 

17.1
Conversions. Lender has the right at any time after the issuance date of this Note until the outstanding balance has been
paid in full, at its election, to convert (“Conversion”) all or any portion of the outstanding balance of this
Note into shares (“Conversion Shares”) of fully paid and non-assessable common stock, $0.001 par value per
share (“Common Stock”), of Borrower as per the following conversion formula: the number of Conversion Shares
equals the amount being converted (the “Conversion Amount”) divided by the Conversion Price (as defined below).
Conversion notices (each, a “Conversion Notice”) may be effectively delivered to Borrower by any method set
forth in the “Notices” Section of the Purchase Agreement, and all Conversions shall be cashless and not require further
payment from Lender.

 

17.2
Conversion Price. Subject to the adjustments set forth herein, the conversion price for each Conversion shall be calculated
pursuant to the following formula: 80% multiplied by the lowest closing price of the Common Stock during the ten (10) Trading
Days immediately preceding the applicable Conversion (the “Conversion Price”). As used herein, the term “Trading
Day” shall mean any day on which Nasdaq is open for trading. Notwithstanding the foregoing, in no event shall the Conversion
Price be less than $1.00.”

 

(c)
The following provision shall be added to each of the Notes as Section 18 (with respect to Note #1) and Section 19 (with respect
to Note #2):

 

“18.
Ownership Limitation. Notwithstanding anything to the contrary contained in this Note, Borrower shall not effect any conversion
of this Note to the extent that after giving effect to such conversion would cause Lender (together with its affiliates) to beneficially
own a number of shares exceeding 4.99% of the number of shares of Common Stock outstanding on such date (including for such purpose
the shares of Common Stock issuable upon such issuance) (the “Maximum Percentage”). For purposes of this section,
beneficial ownership of Common Stock will be determined pursuant to Section 13(d) of the 1934 Act. By written notice to Borrower,
Lender may increase, decrease or waive the Maximum Percentage as to itself but any such waiver will not be effective until the
61st day after delivery thereof. The foregoing 61-day notice requirement is enforceable, unconditional and non-waivable and shall
apply to all affiliates and assigns of Lender.”

 

(d)
The following provision shall be added to each of the Notes as Section 19 (with respect to Note #1) and Section 20 (with respect
to Note #2):

 

“19.
Issuance Cap. Notwithstanding anything to the contrary contained in this Note, Borrower and Lender agree that the total
cumulative number of shares of Common Stock issued to Lender hereunder together with all other Transaction Documents, including
all shares of Common Stock that have been issued pursuant to Exchange Agreements, may not exceed the requirements of Nasdaq Listing
Rule 5635(d) (“Nasdaq 19.99% Cap”). Once the Nasdaq 19.99% Cap is reached, any remaining Outstanding Balance
must be repaid in cash.”

 

    2

     

    

 

3.
Representations and Warranties. In order to induce Lender to enter into this Amendment, Borrower, for itself, and for its
affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows:

 

(a)
Borrower has full power and authority to enter into this Amendment and to incur and perform all obligations and covenants contained
herein, all of which have been duly authorized by all proper and necessary action. No consent, approval, filing or registration
with or notice to any governmental authority is required as a condition to the validity of this Amendment or the performance of
any of the obligations of Borrower hereunder, other than (i) the filings required under applicable federal state securities law,
and (ii) application(s) to each applicable trading market for the listing of the shares of Common Stock issued and issuable under
the Notes.

 

(b)
There is no fact known to Borrower or which should be known to Borrower which Borrower has not disclosed to Lender on or prior
to the date of this Amendment which would or could materially and adversely affect the understanding of Lender expressed in this
Amendment or any representation, warranty, or recital contained in this Amendment.

 

(c)
Except as expressly set forth in this Amendment, Borrower acknowledges and agrees that neither the execution and delivery of this
Amendment nor any of the terms, provisions, covenants, or agreements contained in this Amendment shall in any manner release,
impair, lessen, modify, waive, or otherwise affect the liability and obligations of Borrower under the terms of the Transaction
Documents.

 

(d)
Borrower has no defenses, affirmative or otherwise, rights of setoff, rights of recoupment, claims, counterclaims, actions or
causes of action of any kind or nature whatsoever against Lender, directly or indirectly, arising out of, based upon, or in any
manner connected with, the transactions contemplated hereby, whether known or unknown, which occurred, existed, was taken, permitted,
or begun prior to the execution of this Amendment and occurred, existed, was taken, permitted or begun in accordance with, pursuant
to, or by virtue of any of the terms or conditions of the Transaction Documents. To the extent any such defenses, affirmative
or otherwise, rights of setoff, rights of recoupment, claims, counterclaims, actions or causes of action exist or existed, such
defenses, rights, claims, counterclaims, actions and causes of action are hereby waived, discharged and released. Borrower hereby
acknowledges and agrees that the execution of this Amendment by Lender shall not constitute an acknowledgment of or admission
by Lender of the existence of any claims or of liability for any matter or precedent upon which any claim or liability may be
asserted.

 

(e)
Borrower represents and warrants that as of the date hereof no Events of Default or other material breaches exist under the Transaction
Documents or have occurred prior to the date hereof.

 

4.
Certain Acknowledgments. Each of the parties acknowledges and agrees that no property or cash consideration of any kind
whatsoever has been or shall be given by Lender to Borrower in connection with any amendment to the Notes granted herein.

 

    3

     

    

 

5.
Other Terms Unchanged. The Notes, as amended by this Amendment, remain and continue in full force and effect, constitute
legal, valid, and binding obligations of each of the parties, and are in all respects agreed to, ratified, and confirmed. Any
reference to the Notes after the date of this Amendment is deemed to be a reference to the Notes as amended by this Amendment.
If there is a conflict between the terms of this Amendment and the Notes, the terms of this Amendment shall control. No forbearance
or waiver may be implied by this Amendment. Except as expressly set forth herein, the execution, delivery, and performance of
this Amendment shall not operate as a waiver of, or as an amendment to, any right, power, or remedy of Lender under the Notes,
as in effect prior to the date hereof. For the avoidance of doubt, this Amendment shall be subject to the governing law, venue,
and Arbitration Provisions, as set forth in the Notes.

 

6.
No Reliance. Borrower acknowledges and agrees that neither Lender nor any of its officers, directors, members, managers,
equity holders, representatives or agents has made any representations or warranties to Borrower or any of its agents, representatives,
officers, directors, or employees except as expressly set forth in this Amendment and the Transaction Documents and, in making
its decision to enter into the transactions contemplated by this Amendment, Borrower is not relying on any representation, warranty,
covenant or promise of Lender or its officers, directors, members, managers, equity holders, agents or representatives other than
as set forth in this Amendment.

 

7.
Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original,
but all of which together shall constitute one instrument. The parties hereto confirm that any electronic copy of another party’s
executed counterpart of this Amendment (or such party’s signature page thereof) will be deemed to be an executed original
thereof.

 

8.
Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Amendment and the consummation of the transactions
contemplated hereby.

 

[Remainder
of page intentionally left blank]

 

    4

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Amendment as of the date set forth above.

 

	 	LENDER:
	 	 
	 	Atlas
    Sciences, LLC
	 	 
	 	By: 	/s/ John Finlayson
	 	 	John Finlayson, CEO

 

	 	BORROWER:
	 	 
	 	CBAK
    Energy Technology, Inc.
	 	 
	 	By: 	/s/ Yunfei Li

	 	Printed Name: 	Yunfei
    Li

	 	Title:  	Chief Executive Officer

 

 

 

[Signature Page to Amendment to Promissory
Notes]

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]